% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Choudhary:850812,
      author       = {Choudhary, G. and Langen, K. J. and Galldiks, N. and
                      Mcconathy, J.},
      title        = {{I}nvestigational {PET} tracers for {H}igh-grade
                      {G}liomas.},
      journal      = {The quarterly journal of nuclear medicine and molecular
                      imaging},
      volume       = {62},
      number       = {3},
      issn         = {0392-0208},
      address      = {Torino},
      publisher    = {Ed. Minerva Medica},
      reportid     = {FZJ-2018-04583},
      pages        = {281-94},
      year         = {2018},
      abstract     = {High-grade gliomas (HGGs) are the most common primary
                      malignant tumors of the brain, with glioblastoma (GBM)
                      constituting over $50\%$ of all the gliomas in adults. The
                      disease carries very high mortality, and even with optimal
                      treatment, the median survival is 2-5 years for anaplastic
                      tumors and 1-2 years for GBMs. Neuroimaging is critical to
                      managing patients with HGG for diagnosis, treatment
                      planning, response assessment, and detecting recurrent
                      disease. Magnetic resonance imaging (MRI) is the cornerstone
                      of imaging in neuro-oncology, but molecular imaging with
                      positron emission tomography (PET) can overcome some of the
                      inherent limitations of MRI. Additionally, PET has the
                      potential to target metabolic and molecular alterations in
                      HGGs relevant to prognosis and therapy that cannot be
                      assessed with anatomic imaging. Many classes of PET tracers
                      have been evaluated in HGG including agents that target cell
                      membrane biosynthesis, protein synthesis, amino acid
                      transport, DNA synthesis, the tricarboxylic acid (TCA)
                      cycle, hypoxic environments, cell surface receptors, blood
                      flow, vascular endothelial growth factor (VEGF), epidermal
                      growth factor (EGFR), and the 18-kDa translocator protein
                      (TSPO), among others. This chapter will provide an overview
                      of PET tracers for HGG that have been evaluated in human
                      subjects with a focus on tracers that are not yet in
                      widespread use for neuro-oncology.},
      cin          = {INM-3 / INM-4},
      ddc          = {570},
      cid          = {I:(DE-Juel1)INM-3-20090406 / I:(DE-Juel1)INM-4-20090406},
      pnm          = {572 - (Dys-)function and Plasticity (POF3-572)},
      pid          = {G:(DE-HGF)POF3-572},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:29869489},
      UT           = {WOS:000445240400007},
      doi          = {10.23736/S1824-4785.18.03105-9},
      url          = {https://juser.fz-juelich.de/record/850812},
}